KRAS and adenocarcinoma: The combined prevalence of BRAF and KRAS mutations (78.6%) in serrated adenocarcinomas was higher than in non-serrated adenocarcinomas (27.1%; P < 0.001; Table 4), and the combined prevalence of BRAF and KRAS mutations in serrated adenocarcinomas with a residual serrated adenoma component reached 85.7% (24/28).